The pattern of CD10 expression in selected pathologic entities of the prostate gland

Tawfic, Shereen O.

doi:10.1016/s0046-8177(03)00077-7

Cited by 33 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three CD10-staining patterns were reported: the apical/luminal CD10 staining pattern was detected in small and large intestine, proximal convoluted tubules of kidney, prostatic ductal epithelial cells, and in well to moderately differentiated adenocarcinomas of colon, pancreas, and prostate [2,18] ; the diffuse cytoplasmic staining pattern was seen in urothelial carcinoma, thyroid follicular carcinoma, and various poorly differentiated adenocarcinomas, melanomas, and endometrial stromal tumors [2,7,10,15,18] , and a membranous/Golgi staining pattern was seen in follicular carcinomas, mesonephric tumors, and renal cell carcinomas [2,7,15] . In our study, we observed cytoplasmic staining in both normal and neoplastic bladder epithelia.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, the declined CD10 expression and/or activity may act indirectly as a mitogen by allowing the activity of these factors to be unchecked [18] . There is increasing evidence that neuropeptides may infl uence growth, angiogenesis, and metastasis formation.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, several studies have reported CD10 expression in various nonhematolymphoid normal tissues, including lung alveolar epithelium, liver canaliculi, glomerular cells, renal proximal tubules, epithelial cells of the intestines, prostatic and epididymal epithelial cells, breast myoepithelial cells, endometrial and bone marrow stromal cells, and various types of neoplasms [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] . It has been found that CD10 is expressed in renal cell carcinoma, hepatocellular carcinoma, prostate carcinoma, endometrial stromal tumor, rhabdomyosarcoma, pancreatic adenocarcinoma, schwannoma, and malignant melanoma [2,10,14,18] . By contrast, breast, stomach, and colon carcinoma cells express CD10 at much lower levels [3,6,16] .…”

Section: Introductionmentioning

confidence: 99%

“…Because CD10 is a neutral endopeptidase that regulates the concentration of various bioactive neuropeptides, the decline in CD10 expression and/or activity may act indirectly as a mitogen [18] . There is increasing evidence that neuropeptides may infl uence growth, angiogenesis, and metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

CD10 Expression in Urothelial Bladder Carcinomas: A Pilot Study

Bircan¹,

Çandir²,

Kapucuoğlu³

et al. 2006

Urol Int

View full text Add to dashboard Cite

Objectives: The aims of this study were to investigate the expression of CD10 in normal bladder tissue and urothelial bladder carcinomas and to clarify its association with histopathological variables. Materials and Methods: A total of 79 urothelial bladder carcinomas were selected from routine archival material. All cases were reevaluated histopathologically and graded according to the World Health Organization (WHO) 1973, WHO/ISUP 1998, and WHO 1999 systems. The TNM system was used for their pathological staging. CD10 immunohistochemical staining was performed in selected slides. Results: Tumoral cases consisted of 74 men (93.7%) and 5 women (6.3%). According to the pathological stage, 25 (31.6%), 33 (41.8%), and 21 (26.6%) cases had pTa, pT1, and pT2–3 carcinomas, respectively. 34 of 79 (43%) urothelial carcinomas and only 1 of 11 (9.1%) nontumoral cases showed positive CD10 immunostaining. It was a cytoplasmic diffuse or granular immunostaining pattern both in nontumoral and tumoral urothelia. There was no statistically significant difference between tumoral and nontumoral cases with respect to CD10 reactivity (p = 0.051), but there was a trend toward significance. In urothelial tumors, there was a significant inverse correlation between pathological stages and CD10 immunoreactivity (p = 0.036, r = –0,237). There was also a statistically significant difference between pTa and pT2–3 urothelial tumors in relation to the CD10 expression (p = 0.034). No association was detected between CD10 expression and grades according to all systems used (p > 0.05). Conclusions: According to our findings, the CD10 expression in noninvasive carcinomas showed a higher level than that in invasive carcinomas, and it is inversely correlated with the pathological stage. CD10 may play an important role in the progression of urothelial bladder carcinomas, and downregulation probably facilitates invasion, especially muscle invasion.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

CD10 Expression in Urothelial Bladder Carcinomas: A Pilot Study

Bircan¹,

Çandir²,

Kapucuoğlu³

et al. 2006

Urol Int

View full text Add to dashboard Cite

show abstract

“…This enzyme is known to regulate biological activities of peptide substrates by reducing the local concentrations available for receptor binding and signal transduction [30]. This molecule can be normally expressed by numerous tissues and, accordingly, loss or decrease of CD10 expression has been shown to contribute to the development or the progression in many types of malignancies, including renal cancer [9], invasive bladder cancer [20], poorly differentiated stomach cancer [29], small cell and non-small cell lung cancer [6], endometrial cancer [27,28], and prostate cancer [7,33]. Indeed, reduced CD10 expression may promote peptide-mediated proliferation by allowing and accumulating higher peptide concentrations at the cell surface and may facilitate the development or progression of neoplasia [21].…”

Section: Introductionmentioning

confidence: 99%

CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression

et al. 2006

View full text Add to dashboard Cite

CD10 is a cell surface zinc metalloprotease expressed through a variety of normal cell types, including lymphoid precursor cells, germinal center B lymphocytes, and some epithelial cells. Many studies showed that CD10 expression is associated with the tumor progression of a large variety of cancers, such as breast and colorectal carcinomas. The aim of this study was to investigate the expression of CD10 in nasopharyngeal carcinoma (NPC). The expression of CD10 was immunohistochemically examined in 47 paraffin embedded NPC biopsies from Tunisian patients compared with 16 reactional nasopharyngeal mucosas. A significant expression of CD10 was observed in stromal fusiform cells in 46.8% of NPC cases but was not in malignant and normal epithelial cells. There was no significant expression of CD10 in control group. The stromal expression of CD10 was more frequently detected in advanced clinical stage than early stage (56 vs 23%; p=0.04) and in patients older than 25 years than in patients under 25 years (56.2 vs 26.5%; p=0.05). Our study is the first in investigating CD10 expression in nasopharyngeal carcinoma and showed that CD10 expression by stromal cells in this malignancy play an important role in tumor progression, particularly in older patients.

show abstract